Prostate Cancer - Results from #280

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201). September 19, 2024

Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer. September 19, 2024

Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project. September 19, 2024

Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis. September 19, 2024

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. September 19, 2024

Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. September 19, 2024

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. September 19, 2024

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. September 19, 2024

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. September 19, 2024

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. September 18, 2024

Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging. September 18, 2024

Trifecta Outcomes After Use of 3-Dimensional Digital Models for Planning of Robotic Prostatectomy: A Secondary Analysis of a Randomized Clinical Trial. September 18, 2024

Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making. September 18, 2024

Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study. September 18, 2024

Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. September 18, 2024

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer. September 18, 2024

CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. September 18, 2024

West African Genetic Ancestry, Neighborhood Deprivation, and Prostate Cancer. September 18, 2024

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. September 18, 2024

Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors September 17, 2024

Page 15 of 1438